253 related articles for article (PubMed ID: 37568648)
1. Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm.
Ozer M; Vegivinti CTR; Syed M; Ferrell ME; Gonzalez Gomez C; Cheng S; Holder-Murray J; Bruno T; Saeed A; Sahin IH
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568648
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future.
Sahin IH; Zhang J; Saridogan T; Gorantla V; Rhree J; Malhotra M; Thomas R; Hsu D; Saeed A
JCO Oncol Pract; 2023 May; 19(5):251-259. PubMed ID: 36862965
[TBL] [Abstract][Full Text] [Related]
3. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
Gervaso L; Ciardiello D; Oliveira RA; Borghesani M; Guidi L; Benini L; Algeri L; Spada F; Zampino MG; Cella CA; Fazio N
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782539
[TBL] [Abstract][Full Text] [Related]
7. Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers.
Fazio R; Audisio A; Daprà V; Conti C; Benhima N; Abbassi FZ; Assaf I; Hendlisz A; Sclafani F
Cancer Treat Rev; 2024 Jul; 128():102752. PubMed ID: 38772170
[TBL] [Abstract][Full Text] [Related]
8. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
Tan E; Sahin IH
Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
[No Abstract] [Full Text] [Related]
9. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
10. Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting.
Boutin M; Gill S
Ther Adv Med Oncol; 2023; 15():17588359231162577. PubMed ID: 37007634
[TBL] [Abstract][Full Text] [Related]
11. Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era.
Shimozaki K; Nakayama I; Hirota T; Yamaguchi K
Cells; 2023 Mar; 12(7):. PubMed ID: 37048122
[TBL] [Abstract][Full Text] [Related]
12. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
13. Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature.
San-Román-Gil M; Martínez-Delfrade I; Albarrán-Fernández V; Guerrero-Serrano P; Pozas-Pérez J; Chamorro-Pérez J; Rosero-Rodríguez D; Sotoca-Rubio P; Barrill-Corpa AM; Alia-Navarro V; González-Merino C; García-de-Quevedo-Suero C; López V; Ruz-Caracuel I; Perna-Monroy C; Ferreiro-Monteagudo R
Front Immunol; 2024; 15():1352262. PubMed ID: 38361927
[TBL] [Abstract][Full Text] [Related]
14. Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type.
Matsubayashi H; Oishi T; Sasaki K; Abe M; Kiyozumi Y; Higashigawa S; Niiya F; Sato J; Ishiwatari H; Imai K; Hotta K; Kishida Y; Takada K; Ono H; Yamazaki K; Yasui H; Kenmotsu H; Kado N; Kagawa H; Shiomi A; Sugiura T; Bando E; Nishimura S; Hatakeyama K; Serizawa M; Harada R; Sugino T
Hum Pathol; 2023 May; 135():54-64. PubMed ID: 36596344
[TBL] [Abstract][Full Text] [Related]
15. A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer.
Endo E; Okayama H; Saito K; Nakajima S; Yamada L; Ujiie D; Kase K; Fujita S; Endo H; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
Mol Cancer Res; 2020 Sep; 18(9):1402-1413. PubMed ID: 32493700
[TBL] [Abstract][Full Text] [Related]
16. The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients.
Germani MM; Carullo M; Boccaccino A; Conca V; Masi G
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139613
[TBL] [Abstract][Full Text] [Related]
17. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358
[TBL] [Abstract][Full Text] [Related]
18. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
[TBL] [Abstract][Full Text] [Related]
19. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
Eso Y; Shimizu T; Takeda H; Takai A; Marusawa H
J Gastroenterol; 2020 Jan; 55(1):15-26. PubMed ID: 31494725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
